BRPI0915781A2 - oxazolopiridimas como agonista do receptor edg-1 - Google Patents

oxazolopiridimas como agonista do receptor edg-1

Info

Publication number
BRPI0915781A2
BRPI0915781A2 BRPI0915781A BRPI0915781A BRPI0915781A2 BR PI0915781 A2 BRPI0915781 A2 BR PI0915781A2 BR PI0915781 A BRPI0915781 A BR PI0915781A BR PI0915781 A BRPI0915781 A BR PI0915781A BR PI0915781 A2 BRPI0915781 A2 BR PI0915781A2
Authority
BR
Brazil
Prior art keywords
oxazolopyridimes
edg
receptor agonist
agonist
receptor
Prior art date
Application number
BRPI0915781A
Other languages
English (en)
Portuguese (pt)
Inventor
Dieter Kadereit
Matthias Schaefer
Werngard Czechtizky
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0915781A2 publication Critical patent/BRPI0915781A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0915781A 2008-07-15 2009-07-02 oxazolopiridimas como agonista do receptor edg-1 BRPI0915781A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290694 2008-07-15
PCT/EP2009/004770 WO2010006704A1 (en) 2008-07-15 2009-07-02 Oxazolopyrimidines as edg-1 receptor agonists

Publications (1)

Publication Number Publication Date
BRPI0915781A2 true BRPI0915781A2 (pt) 2015-11-10

Family

ID=39967817

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915781A BRPI0915781A2 (pt) 2008-07-15 2009-07-02 oxazolopiridimas como agonista do receptor edg-1

Country Status (20)

Country Link
US (1) US8735387B2 (de)
EP (2) EP2318415B1 (de)
JP (1) JP5449346B2 (de)
KR (1) KR20110042286A (de)
CN (1) CN102159582B (de)
AR (1) AR072496A1 (de)
AU (1) AU2009270511B2 (de)
BR (1) BRPI0915781A2 (de)
CA (1) CA2730843A1 (de)
CL (1) CL2011000071A1 (de)
CO (1) CO6331436A2 (de)
IL (1) IL210639A0 (de)
MA (1) MA32455B1 (de)
MX (1) MX2011000211A (de)
NZ (1) NZ590377A (de)
RU (1) RU2503680C2 (de)
TW (1) TW201016707A (de)
UY (1) UY31981A (de)
WO (1) WO2010006704A1 (de)
ZA (1) ZA201008786B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI478929B (zh) 2010-01-13 2015-04-01 Sanofi Aventis 含２，５，７－經取代唑并嘧啶環之羧酸衍生物
AR079980A1 (es) 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
SG182474A1 (en) * 2010-01-14 2012-08-30 Sanofi Sa Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring
AU2011206615B2 (en) * 2010-01-14 2015-03-19 Sanofi Carboxylic acid derivatives having A 2,5-substituted oxazolopyrimidine ring
UY33181A (es) * 2010-01-14 2011-08-31 Sanofi Aventis Derivados de oxazolopirimidina 2,5-sustituidos.
CN104072408B (zh) 2010-03-12 2016-09-14 日本曹达株式会社 含有吡啶环的化合物、及卤代甲基吡啶衍生物以及四唑基肟衍生物的制造方法
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
US8735402B2 (en) * 2011-07-07 2014-05-27 Sanofi Cycloalkyloxycarboxylic acid derivatives
US8907093B2 (en) 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
CA2871637A1 (en) 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
UY34763A (es) 2012-04-26 2013-10-31 Bristol Myers Squibb Co Inhibidores de la agregación plaquetaria
US10577308B2 (en) 2015-03-26 2020-03-03 The Florey Institute Sodium channel modulators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3679682A (en) * 1970-04-23 1972-07-25 Fmc Corp CERTAIN 5H-ISOXAZOLO{8 5,4-d{9 PYRIMIDIN-4-ONES
WO2002092603A1 (en) * 2001-05-14 2002-11-21 Novartis Ag Oxazolo-and furopyrimidines and their use in medicaments against tumors
EP1469863A2 (de) 2002-01-18 2004-10-27 Merck & Co., Inc. Selektive s1p1/edg1-rezeptoragonisten
EP1622913A1 (de) 2003-04-25 2006-02-08 University College Cardiff Consultants, Ltd. Heterozyklische verbindungen zur behandlung von viralen infektionen
CA2523677A1 (en) * 2003-04-30 2004-11-11 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
PE20050158A1 (es) * 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
US20070027156A1 (en) 2003-09-09 2007-02-01 Hisao Nakai Crf antagonists and heterobicyclic compounds
AU2004299456B2 (en) 2003-12-17 2010-10-07 Merck Sharp & Dohme Corp. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
US20050239806A1 (en) 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
EP1965807A4 (de) * 2005-11-23 2010-10-27 Epix Delaware Inc S1p-rezeptor-modulierende verbindungen und ihre verwendung
EP1900729A1 (de) * 2006-09-15 2008-03-19 Novartis AG Benzoxazole und Oxazolopyridine und ihre Verwendung als Inhibitoren von Janus-Kinasen

Also Published As

Publication number Publication date
CA2730843A1 (en) 2010-01-21
JP2011527994A (ja) 2011-11-10
CN102159582A (zh) 2011-08-17
EP2318415A1 (de) 2011-05-11
AU2009270511A1 (en) 2010-01-21
EP2318415B1 (de) 2013-02-20
NZ590377A (en) 2011-11-25
US20110190490A1 (en) 2011-08-04
RU2011105388A (ru) 2012-08-20
CO6331436A2 (es) 2011-10-20
US8735387B2 (en) 2014-05-27
CN102159582B (zh) 2014-05-07
TW201016707A (en) 2010-05-01
JP5449346B2 (ja) 2014-03-19
EP2583720A1 (de) 2013-04-24
AR072496A1 (es) 2010-09-01
ZA201008786B (en) 2012-01-25
AU2009270511B2 (en) 2013-07-18
IL210639A0 (en) 2011-03-31
WO2010006704A1 (en) 2010-01-21
KR20110042286A (ko) 2011-04-26
RU2503680C2 (ru) 2014-01-10
CL2011000071A1 (es) 2011-05-06
MX2011000211A (es) 2011-03-03
UY31981A (es) 2010-02-26
MA32455B1 (fr) 2011-07-03

Similar Documents

Publication Publication Date Title
LTPA2020513I1 (lt) S1P receptoriaus agonisto dozavimas
BRPI0915781A2 (pt) oxazolopiridimas como agonista do receptor edg-1
DK2448963T3 (da) T-celle receptorer
FI20080524A0 (fi) Insertteri
ATE535521T1 (de) Hydroxymethyl-pyrrolidine als beta-3-adrenerge rezeptoragonisten
BRPI0919071A2 (pt) um inseridor
BRPI0919228A2 (pt) um inseridor
CR10926A (es) Nuevas 2-aminooxazolinas como ligandos taar1
BRPI0922845A2 (pt) pirazol-4-n-alcoxicarboxamidas como microbiocidas
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
BRPI0916551A2 (pt) dispositivo eletroquímico
BRPI0918064A2 (pt) distribuidor de substância
BRPI0909160A2 (pt) rolamentos
BRPI0820813A2 (pt) Agendamento para gerenciamento de dispositivo móvel
BR112012002824A2 (pt) agonistas de receptor de esfingosina-1-fosfato
NO2019028I1 (no) Cabergoline
BRPI0915562A2 (pt) tamis melhorado
DE112009000730A5 (de) Gleitlager
BRPI0915442A2 (pt) tamis melhorado
NO20081295L (no) Dempeanordning
BRPI0918656A2 (pt) dosador
BRPI0910741A2 (pt) arilciclopentenos substituídos como agonistas de prostaglantina ep2
BRPI0907519A2 (pt) Antagonistas farmacoforos-pde4-muscarínicos duais
MA31558B1 (fr) Arriere-plan technologique
TH106988B (th) ออกซะโซโลพิริมิดีนเป็น Edg-1 รีเซพเตอร์ แอกโกนิสท์

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2376 DE 19-07-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.